Invivyd, Inc.

NasdaqGM IVVD

Invivyd, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD 77.77 M

Invivyd, Inc. Net Cash Used For Investing Activities is USD 77.77 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 21.61% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

Invivyd, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 63.95 M, a 38.84% change year over year.
Invivyd, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 46.06 M.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

NasdaqGM: IVVD

Invivyd, Inc.

CEO	Dr. Robert D. Allen Ph.D.
IPO Date	Aug. 6, 2021
Location	United States
Headquarters	1601 Trapelo Road
Employees	94
Sector	Healthcare
Industries Vaccines Biotechnology Clinical Trials Pharmaceuticals

Description

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

Key trends

Past 5 years